Summit Therapeutics Inc. (SMMT)Healthcare | Biotechnology | Miami, United States | NasdaqGM
25.15 USD
+0.73
(2.989%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 25.19 +0.04 (0.159%) ⇧ (April 17, 2026, 7:57 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:12 p.m. EDT
Summit Therapeutics (SMMT) is currently in a volatile phase, with mixed signals from the options market indicating potential for both upward and downward movements. The recent news and analyst recommendations suggest a positive outlook, but the fundamental data shows negative earnings and a high overall risk. The short-term momentum is weak, and there is no dividend yield to consider. Long-term investors may want to wait for more clarity on the company's financials and future prospects before committing. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.085837 |
| AutoTheta | 0.085883 |
| MSTL | 0.085965 |
| AutoARIMA | 0.120058 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 9.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.004 |
| Excess Kurtosis | 0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.171 |
| Market Cap | 19,500,621,824 |
| Forward P/E | -21.32 |
| Beta | -1.37 |
| Previous Name | Summit Therapeutics plc |
| Website | https://www.smmttx.com |
As of April 11, 2026, 3:12 p.m. EDT: Options activity shows mixed signals. The ATM IV for calls is high, indicating potential volatility, while there is significant OI in both calls and puts, suggesting uncertainty. The presence of major OI walls and new flows indicates that traders are positioning for both upward and downward movements. The overall options data suggests a cautious approach, with traders possibly anticipating a range-bound or volatile price movement in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.00277555 |
| Address1 | 601 Brickell Key Drive |
| Address2 | Suite 1000 |
| All Time High | 36.91 |
| All Time Low | 0.66 |
| Ask | 25.67 |
| Ask Size | 23 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 2,951,260 |
| Average Daily Volume3 Month | 2,661,706 |
| Average Volume | 2,661,706 |
| Average Volume10Days | 2,951,260 |
| Beta | -1.367 |
| Bid | 24.79 |
| Bid Size | 23 |
| Board Risk | 10 |
| Book Value | 0.85 |
| City | Miami |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.15 |
| Current Ratio | 9.869 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 25.48 |
| Day Low | 24.06 |
| Debt To Equity | 3.171 |
| Display Name | Summit Therapeutics |
| Earnings Call Timestamp End | 1,771,882,200 |
| Earnings Call Timestamp Start | 1,771,882,200 |
| Earnings Timestamp | 1,771,880,400 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | -1,094,278,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -17.188 |
| Enterprise Value | 18,808,066,048 |
| Eps Current Year | -0.87582 |
| Eps Forward | -1.17938 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.9455 |
| Fifty Day Average Change | 8.2045 |
| Fifty Day Average Change Percent | 0.48416987 |
| Fifty Two Week Change Percent | -0.277555 |
| Fifty Two Week High | 36.91 |
| Fifty Two Week High Change | -11.76 |
| Fifty Two Week High Change Percent | -0.31861284 |
| Fifty Two Week Low | 13.83 |
| Fifty Two Week Low Change | 11.32 |
| Fifty Two Week Low Change Percent | 0.8185105 |
| Fifty Two Week Range | 13.83 - 36.91 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,425,565,800,000 |
| Float Shares | 133,875,850 |
| Forward Eps | -1.17938 |
| Forward P E | -21.324762 |
| Free Cashflow | 84,078,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 265 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.82621 |
| Held Percent Institutions | 0.15539 |
| Implied Shares Outstanding | 775,372,700 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida. |
| Long Name | Summit Therapeutics Inc. |
| Market | us_market |
| Market Cap | 19,500,621,824 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_11611587 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -1,079,586,048 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 19,500,623,405 |
| Number Of Analyst Opinions | 14 |
| Open | 24.55 |
| Operating Cashflow | -322,929,984 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 305 203 2034 |
| Post Market Change | 0.040000916 |
| Post Market Change Percent | 0.15904936 |
| Post Market Price | 25.19 |
| Post Market Time | 1,776,470,228 |
| Prev Name | Summit Therapeutics plc |
| Previous Close | 24.42 |
| Price Eps Current Year | -28.715946 |
| Price Hint | 2 |
| Price To Book | 29.588234 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.775 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.70588 |
| Region | US |
| Regular Market Change | 0.73 |
| Regular Market Change Percent | 2.98935 |
| Regular Market Day High | 25.48 |
| Regular Market Day Low | 24.06 |
| Regular Market Day Range | 24.06 - 25.48 |
| Regular Market Open | 24.55 |
| Regular Market Previous Close | 24.42 |
| Regular Market Price | 25.15 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 4,876,533 |
| Return On Assets | -1.15276 |
| Return On Equity | -2.06105 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 775,372,700 |
| Shares Percent Shares Out | 0.0446 |
| Shares Short | 34,558,050 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 34,669,041 |
| Short Name | Summit Therapeutics Inc. |
| Short Percent Of Float | 0.2314 |
| Short Ratio | 13.38 |
| Source Interval | 15 |
| State | FL |
| Symbol | SMMT |
| Target High Price | 45.9026 |
| Target Low Price | 12.011553 |
| Target Mean Price | 31.115559 |
| Target Median Price | 33.73831 |
| Total Cash | 713,448,000 |
| Total Cash Per Share | 0.92 |
| Total Debt | 20,890,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.83445 |
| Two Hundred Day Average Change | 5.31555 |
| Two Hundred Day Average Change Percent | 0.26799583 |
| Type Disp | Equity |
| Volume | 4,876,533 |
| Website | https://www.smmttx.com |
| Zip | 33,131 |